Multi-Site Pain Management & Radiology Practice, New Jersey & New York

$2.9M

Revenue

$927K

SDE

4.3x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a multi-site interventional pain management and radiology practice operating across New Jersey and New York, generating roughly $2.9M in annual revenue and about $927K in cash flow. The practice runs from three facilities: two owned buildings in New Jersey (one a recently purchased 3,000 sq. ft. building being developed into a dedicated procedure suite) and a leased 2,000 sq. ft. procedure suite in New York on a flexible month-to-month lease. The asking price of $4M includes the owned real estate, which meaningfully changes how you underwrite the multiple.

The clinical core is interventional pain treatment paired with advanced embolization procedures such as genicular artery embolization (GAE) and shoulder embolization. These are high-reimbursement, minimally invasive alternatives to surgery, and the practice frames them as a differentiated, growing service line with strong patient demand. Growth to date has reportedly been driven by targeted advertising with measurable ROI, particularly for the advanced procedures.

What makes this notable is the combination of recurring, insurance-reimbursed medical demand with a specialty procedure niche that carries better economics than commodity pain management. The owned procedure suites give physical capacity to scale volume without a facility constraint, and there is a defined roadmap to add uterine and prostate embolization plus SIJ fusion. The key underwriting question is how much of the cash flow and reputation is tied to the treating physician(s).

Why we like it

Earnings quality is anchored in insurance-reimbursed medical services, which are largely non-discretionary and get paid regardless of the economic cycle. At $2.92M revenue and $927K cash flow, the roughly 32% margin is healthy for a procedure-heavy practice and reflects the reimbursement premium on embolization work.
The moat is a specialized, high-reimbursement procedure niche (GAE, shoulder embolization) positioned as a surgery alternative, which is harder for a general pain clinic to replicate. Owned procedure suites and a recent build-out create a physical capacity advantage and referral stickiness that commodity clinics lack.
Market tailwinds favor minimally invasive, image-guided interventions as patients and payers increasingly prefer non-surgical options with faster recovery. The stated expansion into uterine and prostate embolization and SIJ fusion taps demand that is demographic-driven and growing, not fad-driven.
The operator advantage is real for a buyer who can recruit or retain interventional physicians and feed the existing marketing engine that already shows measurable ROI. Excess capacity in the owned facilities means incremental procedure volume drops to the bottom line without major new fixed cost.

How to improve it

Audit the payer mix and reimbursement rates per procedure in the first 30 days, then renegotiate the lowest-margin contracts and drop or reprice underwater CPT codes. Even a modest rate lift on the embolization lines compounds directly into cash flow given the fixed-cost base.
Complete the build-out of the new 3,000 sq. ft. procedure suite and schedule it to run at target utilization, since idle owned capacity is the single largest lever here. Model the incremental procedures per week the suite can absorb and staff to fill it rather than leaving it as future potential.
Launch the planned uterine and prostate embolization and SIJ fusion lines with a defined ramp, credentialing, and marketing budget rather than treating them as vague upside. These are high-reimbursement adjacencies that reuse existing imaging infrastructure and referral relationships.
Systematize the marketing that is already producing ROI by tracking cost per acquired patient and cost per procedure by channel. Shift spend toward the advanced procedures where the return is highest and build a referral pipeline from primary care and orthopedics.
Reduce single-physician dependency by adding or contracting additional interventional providers and documenting protocols. This both increases procedure capacity and de-risks the enterprise value that a buyer is underwriting.
Convert the New York month-to-month lease to a longer term or exercise the purchase option if the location performs, to protect a revenue-producing site from landlord risk. Locking the location stabilizes cash flow and improves financeability at resale.
Implement revenue cycle management improvements including denial tracking, faster claim submission, and follow-up on aged receivables. Tightening days-in-AR on a $2.9M practice frees working capital and often uncovers leakage worth six figures annually.

Diligence notes

Establish exactly how much of the cash flow depends on the current treating physician(s) and whether they are staying, since embolization procedures are physician-skill dependent and referral-driven. Confirm employment or transition agreements, credentials, and non-compete terms before assigning any goodwill value.
Separate the real estate value from the operating business value, because the $4M asking price bundles two owned NJ buildings including one still under development. Get independent appraisals so you know the true operating multiple net of real estate and can finance the components appropriately.
Scrutinize payer mix, reimbursement trends, and any concentration in a single insurer or referral source, given embolization codes are newer and reimbursement can shift. Verify that current rates are contractually stable and not reliant on temporary or out-of-network billing dynamics.
Confirm regulatory and compliance standing across two states, including physician licensure, facility accreditation, billing compliance, and any prior audits or payer clawbacks. Multi-state interventional practices carry meaningful regulatory exposure that must be clean before close.
Quantify the capital still required to finish the new procedure suite and validate the claimed capacity upside with actual scheduling and utilization data. 'Ample capacity to scale' is only worth paying for if referral volume and staffing can actually fill it.

Source

Originally listed on Synergy Business Brokers. View original listing →